Generate:Biomedicines is the latest biotech to benefit from a renewed appetite from investors for publicly listed drug developers. Generate—which will list its stock on the Nasdaq this morning under ...
Abstract: Currently, the popularity of large language models (LLMs) for instance, ChatGPT from OpenAI and Gemini from Google is increasing greatly in our lives, due to their unparalleled performance ...
Feb 23 (Reuters) - Drug developer Generate Biomedicines said on Monday it was targeting a valuation of up to $2.17 billion in its U.S. initial public offering, tapping into a resurgent biotech market ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results